Adia Nutrition, Inc. (ADIA) Form 10-Q — Aug 13, 2026
Adia Nutrition posted a sharp operating inflection in Q2 2026: revenue of $485,385 versus $118,146 a year earlier (+311%), led by medical procedures of $329,820 and biologics of $151,750, with quarterly net income of $40,418 against a prior-year net loss of $123,997. For the six months ended June 30, 2026, revenue more than tripled to $661,660 from $189,910, though the company still lost $122,107 (improved from $240,216), ending with cash of $128,115, a stockholders' deficit of $379,781, and an accumulated deficit of $16,095,589.
Key figures
- Eps
- 0
- Revenue
- 661660
- Total Debt
- 835312
- Revenue Yoy
- +248% (six-month revenue rose from $189,910 to $661,660)
- Total Assets
- 744054
- Cash Position
- 128115
- Shares Outstanding
- 94404696
- Q2 Revenue
- 485385
- Q2 Net Income
- 40418
- Total Liabilities
- 1123835
- Q2 Revenue Growth Pct
- +311%
- Q2 Revenue Prior Year
- 118146
- Gross Profit Six Months
- 350157
- Biolete Sale Receivable
- 72361
- Biologics Revenue Six Months
- 221525
- Line Of Credit Draws Six Months
- 235312
- Related Party Accrued Interest
- 60681
- Medical Procedures Revenue Six Months
- 434670
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.